In December 2025, Beijing Surgerii Robotics Company Limited (hereinafter referred to as "Surgerii Robotics" or "the Company"), a leading innovator in the single-port endoscopic surgical robotics area, announced the closing of a USD100 million Series D financing. The funding round was led by Loyal Valley Capital, with participation from several renowned investors including Shanghai Healthcare Capital, V Star Capital, DNV Capital, and Hefei Industrial Investment. The financing will advance the clinical adoption and market promotion of the Company’s core product, the SHURUI Single-Port Surgical Robot ("SHURUI SP Robot") both domestically and internationally, and accelerate the development of the Company’s next-generation products. This will further consolidate the Company’s pioneering position in the global single-port surgical robotics sector.

Joint Support from New and Existing Investors Demonstrates Long-Term Confidence

This financing round has garnered strong backing from both new and existing investors, reflecting their strong endorsement of the Company’s products and sustained optimism about its future development. Loyal Valley Capital, a prominent China-based private equity investor focused on cutting-edge innovations in healthcare and technology, once again led this round, underscoring its firm confidence in the Company’s technology roadmap and growth potential. Other participants include Shanghai Healthcare Capital, a strategic investor in healthcare segment leaders; V Star Capital and DNV Capital, both specializing in innovative healthcare investments; and Hefei Industrial Investment, an investor with extensive experience and industrial resources in hard technology and strategic emerging industries. This diverse and robust shareholder base provides the Company with sustained capital support for continuous innovation, enhanced strategic vision, and strong resource synergies.

Driving the Global Minimally Invasive Surgery Revolution with Innovative Technology

The core technology of the SHURUI SP Robot stems from the innovative "Dual Continuum Mechanism" design developed by Professor Kai Xu of Shanghai Jiao Tong University. This groundbreaking design enabled the development of the SHURUI SP Robot with snake-like surgical instruments, which can perform highly complex and precise surgical procedures through a single minimal 1.8 cm incision.

Surgerii Robotics’ global competitiveness is rooted in its independent and integrated intellectual property portfolio, which comprehensively covers the entire SHURU SP Robotic System. During this financing round, investors conducted a systematic review of the Company's IP portfolio, thoroughly mapping the global technological and patent landscape in surgical robotics. This included a detailed comparative analysis between the SHURUI SP Robot and more than 3,000 valid, granted patents held by leading global endoscopic surgical robot companies across Europe and the United States. The analysis indicates that despite the highly dense patent landscape in this field, the SHURUI SP Robot has achieved disruptive innovation and breakthroughs in key technologies through its proprietary "Dual Continuum Mechanism" technology. This approach distinguishes itself significantly from the existing international surgical robotics patent framework, enabling the company established a forward-looking, multi-layered global patent portfolio.This has laid a solid technological and legal foundation for the freedom to operate and commercialize the SHURUI SP Robot in international markets.

Boosting Clinical Adoption and Global Commercialization

The SHURUI SP Robot obtained the marketing approval from China’s National Medical Products Administration (NMPA) in June 2023, becoming the first approved single-port endoscopic surgical robot in China. In August 2025, it received the CE certification, enabling its use in surgical procedures across urology, gynecology, general surgery, and thoracic surgery for both adult and pediatric patients. It is the only single-port surgical robot with CE certification approved for pediatric use, and the first Chinese surgical robot to be certified for the use in patients of all age group.

To date, the Company has established clinical cooperation with over 70 Grade A tertiary hospitals in China, performed more than 3,000 surgeries, pioneered nearly 50 innovative surgical procedures worldwide and developed over 80 surgical techniques that fill gaps in clinical practice across Asia or China. These procedures range from pancreaticoduodenectomy for pancreatic cancer to surgeries on pediatric patients as young as 7 days old, demonstrating the strength of disruptive technology that achieves smaller surgical trauma while covering an even broader patient population than multi-port surgical robot.

Leveraging the strong support from this new round financing, the Company will further the clinical adoption, develop advanced energy instruments, thereby deepening the therapeutic value of single-port robots in more and complex cases, as well as creating a disruptive systematic solution centered on cutting-edge technology to benefit a wider range of patients.

In 2025, the Company established the European Clinical Excellence Center in collaboration with IRCAD, a world-leading institution for minimally invasive surgical training. Leveraging its unique position as the only single-port surgical robot with CE certification for pediatric use, Surgerii Robotics has set its strategic focus on the high-end European market.

The completion of this financing round comes at a critical juncture, as Surgerii Robotics is deepening its domestic market penetration and accelerating international commercialization. The joint support and resource injection from new and existing investors not only reflect their high recognition of Surgerii Robotics’ innovative technology and systematic global intellectual property holdings, but also further provide the Company with ample capital and strategic confidence for accelerated implementation of its global strategy, enabling broader clinical adoption and large-scale deployment of the SHURUI SP Robot, expanding its global market and service network, accelerating the R&D of next-generation technologies, as well as delivering a new generation of minimally invasive surgical solutions to patients and medical professionals around the world!